ArticleEuropean heart journal. Case reports2026
Intracardiac adenosine triphosphate for cardioversion of supraventricular tachycardia in a hydropic foetus: a case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Foetal supraventricular tachycardia (SVT) can cause foetal hydrops and demise if untreated. Transplacental therapy often fails in severe SVT with foetal hydrops due to impaired placental drug transfer. In the present study, we report the first successful cardioversion of recalcitrant SVT in a hydropic foetus by intracardiac adenosine triphosphate (ATP) administration. Case summary: A 34-year-old woman at 28 + 6 weeks of gestation was admitted for persistent foetal tachycardia, subsequently diagnosed as foetal SVT. After combined transplacental therapy with digoxin and sotalol, the foetal tachycardia remained uncontrolled, with progressive hydrops and deteriorating cardiac function. Ultimately, intracardiac ATP administration was performed and achieved successful cardioversion of the foetal SVT. No procedure-related complications occurred. After the procedure, maternal oral digoxin and sotalol were continued to maintain foetal sinus rhythm. Discussion: Intracardiac ATP administration offers a last-resort salvage therapy for terminating recalcitrant SVT with foetal hydrops, which should be reserved for highly selected patients and performed at specialized centres. The larger studies with longer follow-up are needed to validate this procedure's efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.